1. Subjects who suffer from any form of progressive MS.

2. Any condition which the investigator feels may interfere with participation in the study.

3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,

4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening

5. Previous treatment with immunomodulators within two months prior to screening

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod